Literature DB >> 3485373

Use of rifampin in Haemophilus influenzae type b infections.

K I Li, E R Wald.   

Abstract

Based on evidence that patients with infections due to Haemophilus influenzae type b (HIB) remain colonized after therapy, recommendations for chemoprophylaxis of susceptible contacts have included providing rifampin for patients themselves. However, these recommendations have been made with neither definitive advice concerning the timing of rifampin administration nor any supporting data of efficacy and safety in patients. Our data suggest that rifampin given concurrently with therapeutic antimicrobials is as effective-89% (17/19)--as when given following therapeutic antimicrobials-95% (18/19)--in eradicating pharyngeal HIB. Colonization of the pharynx by HIB was also determined before and during therapy. Almost all patients were colonized before beginning therapy; most were heavily colonized. The density of colonization diminished rapidly during the first 15 to 20 hours of therapy. However, 28% of patients, primarily those who had HIB diseases other than meningitis or did not receive any chloramphenicol, still had detectable colonization after four to six days of antimicrobial therapy.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3485373     DOI: 10.1001/archpedi.1986.02140180115040

Source DB:  PubMed          Journal:  Am J Dis Child        ISSN: 0002-922X


  3 in total

1.  Rifampicin prophylaxis for throat carriage of Haemophilus influenzae type b in patients with invasive disease and their contacts.

Authors:  G L Gilbert; S J MacInnes; I A Guise
Journal:  BMJ       Date:  1991-06-15

2.  Duration of rifampin chemoprophylaxis for contacts of patients infected with Haemophilus influenzae type B.

Authors:  M Green; K I Li; E R Wald; N Guerra; C Byers
Journal:  Antimicrob Agents Chemother       Date:  1992-03       Impact factor: 5.191

3.  Effect of cefotaxime or ceftriaxone treatment on nasopharyngeal Haemophilus influenzae type b colonization in children.

Authors:  P N Goldwater
Journal:  Antimicrob Agents Chemother       Date:  1995-09       Impact factor: 5.191

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.